Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target Raised to $130.00

Mirum Pharmaceuticals (NASDAQ:MIRM) had its price target increased by Stifel Nicolaus from $125.00 to $130.00 in a research report sent to investors on Wednesday,Benzinga reports. Stifel Nicolaus currently has a buy rating on the stock.

Several other research analysts have also commented on MIRM. Leerink Partners dropped their price target on Mirum Pharmaceuticals from $120.00 to $118.00 and set an “outperform” rating for the company in a research report on Thursday, February 26th. Morgan Stanley raised their price objective on Mirum Pharmaceuticals from $95.00 to $123.00 and gave the company an “overweight” rating in a research note on Friday, January 30th. Citizens Jmp reiterated a “market outperform” rating and issued a $132.00 target price on shares of Mirum Pharmaceuticals in a report on Tuesday, April 21st. Weiss Ratings reissued a “sell (d-)” rating on shares of Mirum Pharmaceuticals in a research report on Tuesday, April 21st. Finally, Royal Bank Of Canada decreased their price target on Mirum Pharmaceuticals from $130.00 to $128.00 and set an “outperform” rating on the stock in a report on Thursday, February 26th. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $121.75.

Mirum Pharmaceuticals Price Performance

Shares of NASDAQ:MIRM opened at $96.53 on Wednesday. The company has a debt-to-equity ratio of 0.98, a quick ratio of 2.55 and a current ratio of 2.67. The firm has a fifty day moving average price of $93.78 and a 200 day moving average price of $85.22. Mirum Pharmaceuticals has a fifty-two week low of $40.00 and a fifty-two week high of $109.28. The firm has a market cap of $5.89 billion, a price-to-earnings ratio of -201.10 and a beta of 0.52.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its quarterly earnings results on Wednesday, February 25th. The company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.13). Mirum Pharmaceuticals had a negative net margin of 4.48% and a negative return on equity of 8.53%. The firm had revenue of $148.93 million for the quarter, compared to the consensus estimate of $141.78 million. During the same period in the previous year, the company posted $1.00 earnings per share. Mirum Pharmaceuticals’s quarterly revenue was up 49.8% on a year-over-year basis. As a group, sell-side analysts expect that Mirum Pharmaceuticals will post -1.77 earnings per share for the current fiscal year.

Insider Activity at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, CFO Eric Bjerkholt sold 7,287 shares of Mirum Pharmaceuticals stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $91.98, for a total value of $670,258.26. Following the transaction, the chief financial officer owned 49,788 shares in the company, valued at $4,579,500.24. The trade was a 12.77% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Jolanda Howe sold 4,732 shares of the business’s stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $91.98, for a total transaction of $435,249.36. Following the completion of the transaction, the senior vice president owned 8,429 shares of the company’s stock, valued at $775,299.42. This represents a 35.95% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 89,513 shares of company stock valued at $8,377,249 over the last quarter. 14.36% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the company. Comerica Bank boosted its stake in Mirum Pharmaceuticals by 45.1% in the first quarter. Comerica Bank now owns 895 shares of the company’s stock valued at $40,000 after acquiring an additional 278 shares in the last quarter. AQR Capital Management LLC grew its holdings in Mirum Pharmaceuticals by 307.3% in the first quarter. AQR Capital Management LLC now owns 49,076 shares of the company’s stock worth $2,211,000 after purchasing an additional 37,028 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Mirum Pharmaceuticals by 7.1% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 26,047 shares of the company’s stock worth $1,176,000 after purchasing an additional 1,720 shares in the last quarter. Caxton Associates LLP purchased a new stake in shares of Mirum Pharmaceuticals during the 1st quarter valued at $217,000. Finally, Empowered Funds LLC lifted its holdings in shares of Mirum Pharmaceuticals by 15.4% during the 1st quarter. Empowered Funds LLC now owns 38,386 shares of the company’s stock valued at $1,729,000 after purchasing an additional 5,120 shares during the last quarter.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.